Morgan Stanley Mi Nk Therapeutics, Inc. Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INKT
# of Institutions
29Shares Held
848KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$124,1160.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$88,3320.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny107KShares$56,5440.0% of portfolio
-
Geode Capital Management, LLC Boston, MA98KShares$51,9290.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$46,2130.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $17.9M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...